OrcaGraft (Orca-Q)

Phase 1Biologic

OOrca Biosystems, Inc.

OrcaGraft (Orca-Q) is one of 53 biologic programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaRecruiting

Acute Myeloid LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

60 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

18 5

Vanflyta

Daiichi Sankyo

Phase 3

16 6

Vepesid

AAvyxa

Phase 3

52 7

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

42 8

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 9

Cerubidine

HHikma Pharmaceuticals LLC

Nexavar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Acute Myeloid Leukemia

NCT03802695

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·OOrca Biosystems, Inc.·Phase 1·NCT03802695·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OrcaGraft (Orca-Q). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OrcaGraft (Orca-Q) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OrcaGraft (Orca-Q). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Orca Biosystems, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: OOrca Biosystems, Inc.

OrcaGraft (Orca-Q)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News